Antares Therapeutics just signed a deal with Novartis that could be worth up to $1.9 billion. The goal? To go after cancer targets that have historically been considered undruggable. It's the kind of partnership that makes you sit up and take notice, especially if you follow the biotech space.

Here's how it works: Antares will get $105 million upfront, which is a nice chunk of change to start. But the real upside comes from the potential $1.8 billion in additional payments tied to option exercises, development, regulatory, and commercial milestones. On top of that, Antares is eligible for tiered royalties on global net sales that could reach the low double-digit percentage range. Not bad for a company that's essentially handing over the keys to its discovery platform for a set of targets.

Under the agreement, Antares will handle the early research, using its proprietary platform to go after a limited number of historically undruggable oncology targets. Once Novartis exercises its options, the Swiss pharma giant will take over development and commercialization. Antares, meanwhile, will keep advancing its own pipeline of precision medicines for cancer and other serious diseases alongside this collaboration.

Adam Friedman, Antares' CEO, explained the thinking behind the deal. He said the company built its discovery engine with the goal of systematically unlocking challenging, high-value targets and developing first-in-class precision medicines. The collaboration with Novartis, he noted, allows Antares to expand the reach of that platform while tapping into Novartis' development expertise and global commercial capabilities. In other words, Antares gets to do what it does best—discover—and let Novartis handle the heavy lifting of getting drugs to patients around the world.

The partnership brings together complementary strengths. Antares has expertise in covalent drug discovery, which is a fancy way of saying it designs drugs that form permanent bonds with their targets. That's particularly useful for targets that are hard to hit with traditional drugs. Its platform includes proprietary screening libraries, chemical proteomics capabilities, structure-driven computational chemistry, and a machine-learning suite designed to identify promising first-in-class targets. Novartis brings its massive R&D infrastructure and global reach.

This isn't Novartis' first big bet this year. In March, the company agreed to acquire Excellergy Inc., a private biotech developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments. It also struck a $3 billion deal with Synnovation Therapeutics to strengthen its breast cancer pipeline. So the Antares deal fits a pattern of Novartis using its balance sheet to snap up promising science.

As for the market reaction, Novartis shares were down 0.25% at $152.99 at the time of publication on Wednesday. Nothing dramatic, but investors are probably still digesting the details.

For Antares, this deal is a validation of its platform and a potential financial windfall. For Novartis, it's a chance to get its hands on some cutting-edge science that could lead to new treatments for cancers that have been tough to crack. And for patients, it's another reason to hope that the next wave of cancer therapies might finally take on the undruggable.